Physicochemical Properties
| Molecular Formula | C16H21N7O |
| Molecular Weight | 327.38 |
| CAS # | 2951854-02-5 |
| PubChem CID | 168355517 |
| Appearance | Off-white to light yellow solid powder |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 24 |
| Complexity | 438 |
| Defined Atom Stereocenter Count | 0 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | SHP2-IN-13 (compound 129) significantly suppresses the pERK signaling pathway in a dose-dependent manner, with IC50 values of 0.59 μM and 0.63±0.32 μM in NSCLC cells and NCI–H1975-OR cells, respectively [1]. Shp2-in-13 (0-30 μM; 24 h) decreases pERK levels and receptor tyrosine kinase (RTK)-driven cancer cell growth in NCI-H1975 cells. It also decreases phosphorylated ERK (pERK) levels in receptor tyrosine kinase (RTK)-resistant NSCLC cells [1]. |
| ln Vivo | SHP2-IN-13 (compound 129) (IV/PO; 5 mg/kg) demonstrated a large distribution (13.9 L/kg), medium half-life (T1/2=5.31 h), and high clearance in pharmacokinetic experiments. Its oral bioavailability (F =55.07±7.93%) is higher than SHP099's (F =46%), making it appropriate for use in assessing anti-tumor pharmacodynamics in vivo[1]. Leukemia load was significantly reduced and good antileukemia effectiveness was demonstrated by SHP2-IN-13 (oral gavage; 20 mg/kg; daily). Moreover, it eliminated CD45+ leukemia cells in human blood and spleen samples nearly entirely[1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: NSCLC cells or NCI–H1975-OR cells Tested Concentrations: 0 μM, 0.01 μM, 0.04 μM, 0.1 μM, 0.4 μM, 1.1 μM, 3.3 μM, 10 μM, 30 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibited p-ERK expression in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Murine NSG xenograft model inoculated with FLT3-ITD mutated MV-4-11-luciferase (MV-4-11-Luc) AML cells[1] Doses: 20 mg/kg Route of Administration: Oral gavage; 20 mg/kg; daily Experimental Results: demonstrated an anti-tumor efficacy in AML model. |
| References |
[1]. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment. Eur J Med Chem. 2023 May 5;253:115305. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0546 mL | 15.2728 mL | 30.5455 mL | |
| 5 mM | 0.6109 mL | 3.0546 mL | 6.1091 mL | |
| 10 mM | 0.3055 mL | 1.5273 mL | 3.0546 mL |